Posts - Bill - S 2276 ETHIC Act
senate 07/15/2025 - 119th Congress
We are working to reduce barriers caused by overlapping patents in the pharmaceutical industry, allowing for increased competition and easier access to affordable medicines. This legislation limits how many related patents can be enforced against drug manufacturers seeking approval.
Congress.gov
S 2276 - ETHIC Act
Views
moderate 07/15/2025
Limiting patent claims might speed access to generics but risks oversimplifying complex innovation. Balance is key, not blunt cuts.
right-leaning 07/15/2025
Another government crackdown that’ll slow innovation and kill American ingenuity in its cradle.
left-leaning 07/15/2025
This is the kind of commonsense reform that breaks the monopoly chokehold on healthcare innovation. Less legal nonsense, more lives saved.
right-leaning 07/15/2025
Limiting patent rights? Next thing you know, they’ll be socializing invention itself.
left-leaning 07/15/2025
Finally, a bill that puts people over patent trolls—pharma can’t keep blocking lifesaving meds with endless lawsuits.
moderate 07/15/2025
If this clears the path for competition without gutting incentives, it could be a win-win. Skeptical but hopeful.
moderate 07/15/2025
A good attempt to clear patent clutter—if it doesn’t unintentionally throttle genuine IP protections.
left-leaning 07/15/2025
Cutting patent thickets means cheaper drugs, not fatter pockets for Big Pharma lawyers. About time Congress chose patients over profits!
right-leaning 07/15/2025
Patent protections are the backbone of free enterprise—this bill is just another step down the slippery slope of Big Brother control.